Pfizer CEO said the company will "be at the forefront of testing the most aggressive approaches to maximize the potential of its obesity drug portfolio."

At the TD Cowen conference, Pfizer executives emphasized that the company will adopt bold strategies to optimize its layout in the obesity treatment sector. This statement highlights Pfizer's strategic positioning in the increasingly competitive weight-loss drug market. As global demand for obesity treatment continues to grow, pharmaceutical companies are ramping up their investments in this field. Pfizer's announcement indicates that the company plans to actively innovate and test solutions, striving to secure a significant position in the obesity treatment market.